ai
Roche Agrees to Acquire PathAI for Up to $1.1 Billion
Roche has agreed to buy digital pathology company PathAI in a deal valued at up to $1.1 billion. The transaction comes as the pharmaceutical and diagnostics company expands its presence in artificial intelligence applications for pathology. Seekingalpha.com reported the agreement, noting that shares of Roche traded in focus following the announcement.
May 7, 1:32 PM·1m read1 source
cnbc.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Roche has agreed to acquire PathAI, a digital pathology firm, for up to $1.1 billion. com. The transaction reflects Roche's strategy to strengthen its capabilities in digital pathology and artificial intelligence tools used in medical diagnostics. The acquisition will integrate PathAI's technology into Roche's existing diagnostics portfolio.
PathAI has developed platforms that use artificial intelligence to assist pathologists in analyzing tissue samples for cancer and other diseases. Roche, which already offers a range of diagnostic instruments and tests, expects the addition to expand its offerings in precision medicine.
Following the announcement, Roche shares drew investor attention in trading. The stock is listed under the ticker RHHBF on over-the-counter markets. com reported that shares of another artificial intelligence company in the medical field slipped in reaction to the news.
The deal structure includes potential additional payments that could bring the total value to $1.1 billion. Specific terms regarding the breakdown of upfront and contingent payments were not detailed in initial reports. The transaction remains subject to customary closing conditions.
Roche has been investing in digital health technologies as pathology laboratories increasingly adopt artificial intelligence to improve accuracy and efficiency. The acquisition of PathAI provides Roche with established AI models trained on large datasets of pathology slides.
This move aligns with broader industry trends toward combining pharmaceutical development with advanced diagnostic tools. PathAI, founded as an independent company, has partnered with multiple pharmaceutical firms and healthcare providers in recent years.
